bZ&iQkesZlh ds fojks/ esa dSfeLV nsaxs Kkiu vEckyk] c`tsanz eYgks=kk%& ns'k ds loksZPp U;k;ky; }kjk vkWuykbu iQkesZlh ds tfj, xzkgdksa rd nokb;ka miyC/ djokuk vc Vs<+h [khj gks x;k gS- iatkc esa ;qok u'ks dh fxjÝr esa uk vk,] blds fy, ihlh, (iatkc dSfeLV ,lksfl,'ku) us iatkc ljdkj o iatkc vkS"kf/ iz'kklu dks Kkiu ds ekè;e ls ekax dh fd vfoy- ac vkWuykbu iQkesZlh }kjk nokb;ka cspus okyksa ds f[kykiQ U;k;ky; ds vkns'kksa dh ikyuk dj jkT; ds ;qokvksa dks u'ks dh xrZ esa tkus ls cpkus esa lkFkZd dne mBk,a- mYys[kuh; gS fd vkWuykbu iQkesZlh ds ekè;e ls feyus okyh nokvksa o vU; lkeku ds ckjs es ckj&ckj ns'kHkj ds dbZ dksuksa ls [kqyklk gks pqdk gS fd vkWuykbu iQkesZlh tgka fcuk iQkekZflLV ds nok O;kikj djrh gS tks MªXl ,aM dkWLesfVd ,DV dh vogsyuk Hkh gS rFkk vkWuykbu ds ekè;e ls MqIyhdsV o fuEu Lrj dh nokb;ka jksfx;ksa rd igqapkus dk dke tkus vutkus vkWuykbu IkQkesZlh }kjk fd;k tk jgk gS- vRk% iatkc esa bl izdkj ds fdlh Hkh izfr"Bku dh vfoyac iw.kZ :i ls can fd;k tk,- chlh, ds izns'k vè;{k lqjsanz nqXxy o jkT; egklfpo th,l pkoyk ds vuqlkj 'kh?kz gh ftyk Lrj ij vkS"kf/ iz'kklu o jkT; ljdkj ds iz'kklfud vf/dkfj;ksa dks Kkiu ds ekè;e ls ,d lw=kh dk;ZØe pyk;k tk,xk- jkT; ds ;qok vkWuykbu iQkesZlh ds ekè;e ls u'ks dh nokbZ dh pisV esa uk vk,a vkSj jksxh tks dqN NwV ds ykyp esa vkWuykbu iQkWekZ ls fuEu Lrj dh nokb;ka [kjhn viuh chekfj;ksa dks vkSj vf/d uk c<+k ik,- nqXxy us dgk fd jkT; ds gj 'kgj dLCks xkao Lrj ij fjVsy o gksylsy dh nokvksa ds foØ; gsrq iatkc dsfeLV ,lksfl,'ku ds lnL; vius O;kikfjd izfr"Bku [kqys gq, gSa tks vketu dh t:jrksa vuqlkj nok dks nok ds :i es jksfx;ksa rd igqapkus dk dk;Z dj jgs gSa- ;fn dksbZ nok O;olkbZ nok dks u'ks ds :i esa fdlh dks Hkh miyC/ djokrk gS- jkT; laxBu ftyk laxBu LFkkuh; laxBu fdlh Hkh Lrj ij ml nok O;olkbZ dks laj{k.k ugha nsrk] mYVk ljdkj o vkS"kf/ iz'kklu ds lkFk da/s ls da/k feykdj u'ks dks tM+ ls feVkus ds fy, opuc} gS- Good Relation Never Break Cipla Foundation Awards Scholarships To Students From Goa College Of Pharmacy Goa:- In continuance of its efforts to promote quality education, Cipla Foundation, Ph.:- 020-25231130 the social responsibility arm of Cipla Ltd, has partnered with the Goa College of Pharmacy for the first time to provide scholarships to deserving students from financially disadvantaged backgrounds. This partnership will help selected students with financial support towards their fees for various courses such as, Diploma in Pharmacy, Bachelor of Pharmacy and Master of Pharmacy. The Chief Guest, Dr. G. K. Rao, Principal, Goa College of Pharmacy, felicitated the students with certificates and financial gratification on 5 th December 2019 in the college premises in Panaji. The event was attended by senior officials from Cipla Ltd Goa and Cipla Foundation. The collaboration aims to empower students from lesser privileged families by helping them complete their education and be ready for employment opportunities. Chief Guest, Dr G. K. Rao, Principal, Goa College of Pharmacy, said, “Our focus has been to provide the next generation with apt skills, knowledge and academic excellence, so they can take up roles and run the communi- ty pharmacies. This partnership is a promising step towards achieving this goals.” Commenting on the launch, Ms. Rumana Hamied, Managing Trustee, Cipla Foundation, said, “We are delighted to come together with an institution of repute like the Goa College of Pharmacy to support the aspirations and ambitions of students. It is imperative to nurture a generation of educated, informed and skilled youth who are empowered to create a produc- tive future.” As part of its focus on improving education outcomes, Cipla Foundation supports unique developmental initiatives through its CSR interventions and works closely with local ¶vxj vki lksprs gSa fd Kku ikuk egaxk gS rks] vKkuh cudj ns[kks¸ communities and the government through collaborative partnerships. ¶D;k vkidks Kku gS fd izse dk nsg ls dksbZ lEcU/ ugha\¸ {kf.kdk iqu%LFkkiu ,d tkrk] nwtk vkrk- lkjk lalkj] py ikrk- nkf;Ro ftEesnkfj;ka] Lo;a laHkkyks- nwljksa ds Åij] dHkh uk Vkyks- Hkjkslk gj ckr ij] 'kd er djks- eu esa dgh] FkksM+k fo'okl /jks- ;qojkt flag N% ckWy] N% NDds- ;qojkt gSa] /qu ds iDds- vktdy ykt fygkt laLdkj] lc <d x, gSa- o`} tu rks vc] Fkd ls x, ga- fy[kkoV MkWDVj ifr dk i=k] rc le> esa vk;k- tc iRuh us mls] dSfeLV ls i<+ok;k- bPNk eu esa gSa] vfHkyk"kk- lnk cuh] jgs vk'kk- pyuk iyksa dk vkuk] iyksa dk tkuk- gekjk py ikuk] thou dk rjkuk- &MkWñ ujsUnz ukFk ykgk] Xokfy;j (eñizñ)] eksñ 09753694240- 3 o"kZ rd ?kj cSBs ;g lekpkj i=k i<+us ds fy;s gekjs iatkc uS'kuy cSad ds [kkrk la[;k 1824002100120081] IFSC Code - PUNB0182400 tks fd eSMhdy niZ.k ds uke ls gS] esa :ú 250@& tek dj viuk iwjk irk gekjs iQksu uaú& 09410434811 ij SMS dj nsaA {kf.kdk n`f"V vk¡[kksa dh] vfHkO;fDr- fcuk cksys] eu dh 'kfDr- lkeatL; thou esa] larqyu rks pkfg,- iwjh vk;q] lq[kh th ikbZ,- futh igys Lo;a] dks lq/kjks- fiQj nqfu;k] dks lokjks- lkFk feydj] py ik,- liQy] gks tk,- fur vkSlr dekvks] ij jkst dekvks- vafre {k.k rd] lEeku dks ikvks- vk/kj vk;q gj iy] u;k jax fn[kkrh- >qfjZ;ksa dk vkuk] vuqHko dks n'kkZrh- ikVhZ dqN Msªl] BaM dks Hkqykrs- xehZ dk ,glkl fnykrs- dqN flj ds rqyuk] pkan ls djrs gSa- ogk¡ iQly ugha gS] ;gk¡ cky ugha gS- p;u ru chekj] nok ls lq/kjksa- eu chekj] Lo;a dks lq/kjksa- foijhr vgadkj ikl] rks bZ'oj nwj- bZ 'oj ikl] rks vagdkj nwj- bPNk tkrs&tkrs] lc Hkyk dgsa- nqvk ns ikbZ,] ;gh cl pkfg,- & MkWñ ujsUnz ukFk ykgk Xokfy;j (e-iz-) eksñ 09753698240- dksgjs esa xkM+h pykrs è;ku j[ks nq?kZVuk ls cps] thou cpk;s mRrj Hkkjr esa BaM ds lkFk&lkFk dksgjk Hkh c<+ x;k gS- /qa/ ds dkj.k foftfcfyVh dkiQh de gks x;h gS- ;gh dkj.k gS fd gj jkst lM+dksa ij nq?kZVuk,a gks jgh gS- bu gknlksa esa vHkh rd dbZ ekSrsa gks pqdh gS- dksgjs ds chp lM+d ij lqjf{kr liQj ds fy, pkyd dk tkx:d gksuk t:jh gS- T;knkrj nq?kZVuk,a blfy, gksrh gS fd yksx dksgjk gksus ds ckotwn viuh xkM+h dh jÝrkj /hjs ugha djrs- mUgksus dgk fd ;s è;ku j[kuk t:jh gS ftruh vkidh xkM+h dh LihM gS] mruh gh nq?kZVuk dh laHkkouk c<+ tkrh gS- dSls djsa cpko\ - foftfcfyVh csgn [kjkc gksus ij lM+d ij dyj dh xkbMykbu dks iQkWyks djsa- &iSny] lkbfdy vkSj nks ifg;k ij pyus okys laHko gks rks CySd ;k MkdZ dyj ds diM+s u igusa- &iSny lkbZfdy vkSj nks ifg;k pykus okys jsfM;e tSdsV igusa- & okguksa ij [kklrkSj ls lkbZfdy ij jsfM;e Vsi dk bLrseky djsa tks yksx LdwVj ;k ckbZd ij tkrs gS oks gsyesV ij Hkh jsfM;e Vsi dk bLrseky djsa- & dksgjs esa xkM+h dks lM+d ij ikdZ u djsa] vxj FkksM+h nsj ds fy, lM+d ij xkM+h jksd jgs gSa rks pkjks bafMdsVj vkWu j[ksa- vuqHkoh MkDVjksa dk ijke'kZ ukS,Mk fLFkr lqij Lis'kfyVh vLirky ;FkkFkZ eksñ 8130206637 ds MkWñ uhjt pkS/jh cqyUn'kgj fLFkr ve;s'k gkWfLiVy esa viuh lsok,a nsaxs- gsYiykbZu uañ 8800447777- U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW TO SNDA FOR BRAFTOVI® (ENCORAFENIB) IN COMBINA- TION WITH ERBITUX® (CETUXIMAB) (BRAFTOVI DOUBLET) FOR THE TREATMENT OF BRAFV600E-MUTANT METASTATIC COLORECTAL CANCER AFTER PRIOR THERAPY Pfizer Inc. Mob:- 09039483991, 09997456338, 09887245322 announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemen- tal New Drug Application (sNDA) for BRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) based on results from the Phase 3 BEACON CRC trial, which evaluated the efficacy and safety of BRAFTOVI in combination with ERBITUX with or without MEK- TOVI® (binimetinib) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. As published in The New England Journal of Medicine (NEJM), results from the BEACON CRC trial showed improvements in overall survival (OS) and objective response rates (ORR) for both the BRAFTOVI Doublet and BRAFTOVI Triplet (BRAFTOVI, MEKTOVI and ERBITUX) combination, compared to ERBITUX plus irinotecan- containing regimens (Control).1 In descriptive analyses comparing the Doublet and Triplet arms, the results showed compara- ble efficacy between the Doublet and Triplet in the overall population. The BRAFTOVI Triplet and Doublet showed no unex- pected toxicities. “The FDA’s acceptance of our application for the BRAFTOVI Doublet is highly encouraging news for patients with mCRC harboring a BRAFV600E mutation,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “Currently, there are no FDA-approved treatments specifically for patients with BRAF-mutant mCRC who have received prior treatment.